PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Initiation of Phase 1 Study Marks PepGen’s Transition to a Clinical Stage Company This Phase 1 Healthy Normal Volunteer (HNV) Study will Evaluate Safety and Tolerability as the Primary Objective, and will Begin to Evaluate the Delivery and Target Engagement of PGN-EDO51 to Enable Subsequent Patient Trials BOSTON, April 6, 2022 – PepGen, Inc., …